- Vertical Smart Slide 1
- 2011 Review and Outl…
- Posted 2 days ago
Our favorable outlook for the biotechnology industry remains intact for 2012 and is based on several key drivers
- 2012 Preview: Cancer…
- Posted 44 days ago
2012 represents a period with robust news flow for emerging immuno-oncology companies
- Baker’s Dozen Attemp…
- Posted 96 days ago
November marks Pancreatic Cancer Awareness Month - a baker’s dozen are trying to beat the odds in treating the disease.
- Adjuvants May Hold K…
- Posted 131 days ago
Often overlooked, adjuvants can be an essential part of an effective vaccine and could help advance the field of cancer immunotherapy even further.
- Advances in Radiatio…
- Posted 184 days ago
Following the introduction of targeted agents beginning in the late 1990s, there is a common misconception that the use of older cancer therapies, such as radiation, is on the decline.
Articles
Cancer Immunotherapy: A Roundtable Discussion
Beyond the approvals of both Provenge and Yervoy, there are a number of additional catalysts that could ignite further interest in the field of cancer immunotherapy.
Three Late-Stage Leukemia Company Previews for ASCO
Three companies with late-stage development programs for the treatment of AML are expected to provide updates at the 2011 ASCO annual meeting.
Similarities Between Two Immunotherapies in Cancer
Approval of Bristol-Myers Squibb’s Yervoy® [ipilimumab] for melanoma in March 2011 marked the second victory for the field of immunotherapy in oncology within a year.
Ipilimumab Approval Highlights Immunotherapy Renaissance
On March 25, 2011, Yervoy® [ipilimumab] by Bristol-Myers Squibb became the eleventh mAb approved by the FDA for the treatment of cancer.
Company Spotlights
Agenus Inc.
Agenus Inc. is a biotechnology company working to develop treatments for cancers and infectious diseases. With our strong platform technologies, multiple product candidates are advancing through the clinic. The most suitable patient populations to benefit from our novel vaccine approach have been defined. View the company’s fact sheet (PDF)
Opinion Editorials
Bear Market Advice and Perspectives
Our management and strategy consulting firm was founded in November 2008, which was clearly a difficult period for the U.S. economy and a year that many investors would like to forget. The Dow Jones Industrial average recorded its worst annual performance since 1931 and the NASDAQ Composite had its worst year since inception in 1971. [...]
Innovative Science Briefs
New generation of medicines targeting G-protein coupled receptors (GPCRs)
Heterotrimeric G protein-coupled receptors (GPCRs) are the largest family of cell surface receptors (1) and play a critical role in transmitting signals from outside to inside a cell. GPCRs role in cell physiology and pathophysiology is well documented as nearly all physiological functions are dependent on GCPR signaling (1,2). The activation of a GPCR is [...]
Follow MD Becker Partners